The Latest Breaking News from FDA

The Justice Department is seeking emergency relief from the U.S. Supreme Court in a Texas case involving limited access to the abortion drug mifepristone.

Horizon grew large by snapping up cheap drugs from other companies, marketing them to perfection, and jacking up prices.

Although inflation has shown signs of easing, it remains elevated. Therefore, the possibility of further rate hikes remains. As fears of a recession rise, investors may consider buying fundamentally strong stocks NetScout Systems (NTCT), Central Puerto (CEPU), and Vanda Pharmaceuticals (VNDA), trading at discounts to their peers. Keep reading….

Court upheld part of a Texas judge's ruling halting FDA decision allowing mifepristone to be distributed by mail

A federal appeals court partly granted the Biden administration’s request to put on hold a Texas court ruling overturning FDA approval of the abortion pill, but allowed restrictions that were lifted since 2016 to be reinstated.

Plus: New developments in the Texas abortion drug ruling, fallout from the Riley Gaines event at SFSU, and more...

At the heart of the latest battle over abortion access is a federal judge’s ruling that cites concern about the mental health of women who choose to end their pregnancies.

Mifepristone will remain on the market, but approved only for use up to seven weeks of pregnancy, versus 10 weeks, and it cannot be prescribed by telehealth or mailed, which were already illegal in Texas.

The Biden administration had asked the higher court to stay a decision from a Texas judge while the appeal plays out.

A federal appeals court allowed the nation’s most-used medication abortion drug to remain on the market after Saturday.

People are seeking the advance provision of medication before Friday’s deadline, when the drug may become unavailable